HR Execs on the Move

Bayer

www.bayer.us

 
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Our products are helping to address some of today`s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources. We are improving people`s quality of life by preventing, alleviating or curing diseases. We are helping to provide an ...
  • Number of Employees: 50K-100K
  • Annual Revenue: > $1 Billion
  • www.bayer.us
  • 100 Bayer Boulevard
    Whippany, NJ USA 07981
  • Phone: +49 8624 043000

Executives

Name Title Contact Details
Rachel Koontz
VP R&D Allergy, Cough Cold, Pain & Cardio at Bayer Consumer Health Profile
David Caldwell
Head of Biologics Data Science, Biologics R&D, Bayer Crop Science Profile
David Townson
Executive, Oncology Research and Development : Immuno-Oncology, Cell Therapy Profile
Michelle Lamendola
Global R&D Director, Pipeline & Project Management Profile
Alexander Novak
Head of Laboratory – Process R&D Profile

Jobs

Director Human Resources

Bayer Berkeley, CA
YOUR TASKS AND RESPONSIBILITIES
The primary responsibilities of this role, as Director Human Resources, are to:
Pharma PS West Coast:

Provide leadership for global initiatives/processes and ensure
proper coordination between global and local;

Ensure the US perspective is clear at the global level and
partner in creating solutions;

Similar Companies

Acer Therapeutics

Acer Therapeutics is a biotech company, headquartered in Cambridge, MA, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. Acer`s lead candidate, EDVISO™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type Ehlers-Danlos syndrome (vEDS). Ehlers-Danlos Syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. vEDS is a subtype characterized by severe arterial dissections, ruptures and early death. Complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. Median age of death is estimated to be around 50 years. Patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the COL3A1 gene. There are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the U.S. (Pepin 2014). There are no specific pharmacological treatments for vEDS and medical intervention centers on symptomatic treatment, prophylactic measures and genetic counseling. Acer was awarded orphan drug designation by the FDA in January 2015. Acer`s second candidate, ACER-001, is the first pharmaceutical therapy being developed for patients with Maple Syrup Urine Disease (MSUD). MSUD is a devastating genetic disease – an inborn error of amino acid metabolism. Approximately 800 patients suffer from MSUD in the U.S. and 3,000 worldwide. There are no therapeutic options for MSUD and diet is not enough. Despite careful dietary management, the majority of MSUD patients have chronic neurological and social impairment, as well as life-threatening episodes of intoxication. Acer was awarded orphan drug designation by the FDA in August 2014.

Elixir

Elixir, (formerly EnvisionRxOptions) a wholly owned subsidiary of Rite Aid, is a pharmacy benefits and services company with the unique ability to optimize the full pharmacy care experience.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.

Sagent Pharmaceuticals

Sagent Pharmaceuticals is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Artelon

Artelons technology was developed explicitly to enhance the strength and kinematic demands of reconstructed tendons and ligaments. Artelons Dynamic Matrix restores native motion, resists the necrotic degradation of  strength, and promotes an ideal me...